Astiva Health is a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare. The organization today announced that it has started the process of registering its common shares on the Nasdaq Global Select, marking a crucial step for Astiva Health as it moves toward making a lasting impact in the healthcare industry. According to the announcement, the specifics of the number of shares to be offered and the price range are yet to be determined. The offer is contingent upon market conditions, and there is no assurance regarding the completion, size or terms of the offering. Astiva Health plans to file privately via DRS within the month of December, listing its common shares. Spartan Capital was engaged as the banker/underwriter for this significant milestone in Astiva Health’s journey. Pending approval by regulators, the company is targeting a Q1 IPO.
To view the full press release, visit https://ibn.fm/eYZlq
About Astiva Health
Astiva Health is a fast-growing MAPD health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members. The organization prioritizes a culturally responsive approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Astiva Health’s dedication to serving the underserved population is not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves. Astiva Health invites individuals to join its transformative healthcare experience, where personalized care and lasting well-being take center stage. For more information about Astiva Health and enrollment details, please visit https://astivahealth.com.
NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN